Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HPD drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HPD Recombinant Protein (WT & Catalytic Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 Expressed. |
View HPD Products |
| Gene Delivery | HPD Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HPD Products |
| Benchmark Ab | Anti-HPD Benchmark Antibody Recombinant positive control for target validation. |
View HPD Products |
| Validator | HPD siRNA Set For knockdown verification in functional assays. |
View HPD Products |
| Related Target FAH | FAH (Fumarylacetoacetase) Downstream enzyme in tyrosine catabolism; HT-1 deficient target. |
View FAH Products |
| Related Target TAT | TAT (Tyrosine aminotransferase) Upstream enzyme in the pathway. |
View TAT Products |
| Related Target HGD | HGD (Homogentisate 1,2-Dioxygenase) Alkaptonuria target; pathway neighbor for cross-talk studies. |
View HGD Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzyme Kinetic Studies | High Purity (>95%) Recombinant Protein, strictly verified by mass spec and SDS-PAGE |
| Species Cross-Reactivity (Mouse models) | Human/Mouse/Cyno ortholog proteins available with identical purification specs |
| Lack of Reliable Assay Controls | Sequence-verified benchmark antibodies for IP/WB/IHC included in catalog |
| Target Validation & Specificity | Validated siRNA sets included for cellular knockdown confirmation |
| Related Dioxygenase Off-Target Screening | Homolog panel proteins strictly verified by mass spec for counter-screening |
| False Positives in Inhibition Assays | Catalytic mutant proteins (Fe(II)-binding site variants) as negative controls |
Live HPD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of HPD (4-Hydroxyphenylpyruvate dioxygenase) is critical for managing rare metabolic diseases such as Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU). By inhibiting HPD, the upstream accumulation of toxic metabolites like succinylacetone is prevented. While established small molecules (e.g., nitisinone) are the standard of care, the next wave of R&D is targeting improved safety profiles, once-weekly formulations, and potential applications in other metabolic syndromes. Drug discovery requires precise enzymatic assays to fine-tune inhibitor binding kinetics and minimize off-target effects. Emerging clinical focus also includes gene therapy approaches (AAV-mediated correction) for permanent metabolic restoration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | SOBI, Cycle Pharma | Tyrosinemia Type 1, Alkaptonuria | Enzyme Inhibition Assay (Need high-purity WT HPD Protein) |
| Small Molecule (Next-Gen) | Emerging Biotechs | Tyrosine metabolic disorders | Selectivity Screening (Need Ortholog/Mutant panels) |
| Gene Therapy | Various Academic Labs | Tyrosinemia Type 1 (FAH correction) | Pathway Modulation (Need HPD Ab controls for monitoring) |
| RNAi / siRNA | Early-stage Exploratory | Hereditary Tyrosinemia | Knockdown Efficiency Validation (Need validated HPD siRNA) |
Key Mutations and Functional Domains
HPD contains two VOC (vicinal oxygen chelate) domains (VOC 1 and VOC 2) as per UniProt P32754. Key mutations include dbSNP:rs1154510, dbSNP:rs11833399, and dbSNP:rs137852865 (TYRSN3; uncertain significance). These mutations are relevant for studying enzyme activity and inhibitor selectivity.
Related Targets in Tyrosine Catabolism
- FAH (Fumarylacetoacetase): Downstream enzyme; deficiency causes HT-1. HPD inhibition aims to bypass FAH deficiency.
- TAT (Tyrosine aminotransferase): Upstream enzyme; first step in tyrosine catabolism.
- HGD (Homogentisate 1,2-Dioxygenase): Downstream enzyme; deficiency causes Alkaptonuria.